Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study

A.M. Oza, F. Selle, I. Davidenko, J. Korach, C. Mendiola, P. Pautier, E. Chmielowska, A. Bamias, A. Decensi, Z. Zvirbule, A. González-Martín, R. Hegg, F. Joly, C. Zamagni, A. Gadducci, N. Martin, S. Robb, N. Colombo

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)50-58
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume27
Issue number1
DOIs
Publication statusPublished - 2017

Cite this

Oza, A. M., Selle, F., Davidenko, I., Korach, J., Mendiola, C., Pautier, P., Chmielowska, E., Bamias, A., Decensi, A., Zvirbule, Z., González-Martín, A., Hegg, R., Joly, F., Zamagni, C., Gadducci, A., Martin, N., Robb, S., & Colombo, N. (2017). Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. International Journal of Gynecological Cancer, 27(1), 50-58. https://doi.org/10.1097/IGC.0000000000000836